Why You Should Attend
All major biopharma business decisions and investments are based on revenue forecasting―therefore it is imperative you know how to forecast and challenge forecasts accurately.The focus of this course are the concepts, techniques and approaches which have been proven to work best for biopharmaceuticals.
Our Industry Expert Instructors
Mr. Russ Belden is a biotech commercialization leader with over 33 years of senior leadership experience in strategic marketing, sales management, sales training, and product development. Starting as employee 10 in Genentech’s SSF Commercial organization, he spent 16 years there launching products/indications across multiple therapeutic areas, including playing a pivotal role in launching their BioOncology franchise and left as the Director of Hematology Sales.
As Founder/President & CEO of Bridge Consulting LLC, Russ has worked with over 60 emerging biotech companies over the past 17 years. In addition to commercial assessments for pre-clinical to Phase 2 companies, Russ provides critical commercial leadership to Phase 3 emerging biotech companies as an interim Chief Commercial Officer (iCCO). Acting as the company's iCCO he leads all the commercialization imperatives, establishes the “blueprint” for the Commercial / Medical Affairs organization and develops a 3-year expense budget including all commercialization costs enabling the company to successfully position its lead product(s) for commercial launch while absorbing the risk of a potentially negative Phase 3 readout. Russ is currently the iCCO at three Phase 3 companies.
He also serves as the Commercial Expert for the California Life Sciences Institute’s (CLSI) FAST program.
Dr. William P. Cacheris has over 30 years of experience in the healthcare and pharmaceutical industries. As the founder and president of Tessellon, Dr. Cacheris has extensive knowledge of epidemiology and forecasting across many therapeutic areas. In particular, he is a master of global oncology epidemiology data sources and various disease registries. Using this vast knowledge and experience, Bill uses his forecasting and modeling skills to develop robust and meaningful market assessments that are essential in business planning for pharmaceutical companies ranging from epidemiology, patient segmentation, disease treatment patterns, market analysis and trends, future market dynamics, and forecasted products sales.
Bill’s academic qualifications include a Ph.D. in inorganic chemistry from Florida State University and his M.B.A. from University of Missouri, St. Louis. His background in metal chelates led him to the world of magnetic resonance contrast agents and blood substitute industries which he served for over 7 years. His knowledge of science and business led him to the consulting firm of Kantar Health (formerly The Mattson Jack Group) as Vice President, S&T and Strategic Products, where he lead the global product offerings for forecasting, epidemiology, and oncology for over 10 years. During his tenure at the Kantar Health, he not only gained valuable skills in forecasting and product databases, but also extensive global business experience extending to Europe, China, and Japan, which has enabled Bill to establish key partnerships for Tessellon in these geographies.
Looking forward to seeing you on September 2-3, 2020!
Sincerely,
Stacey Hawkins
CEO, Biotech Primer
